- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00595322
Bevacizumab in the Radiation Treatment of Recurrent Malignant Glioma
Safety of Bevacizumab in the Radiation Treatment of Recurrent Malignant Glioma: A Pilot Study
This is a pilot study. The goal of this study is to test whether Bevacizumab is safe enough in patients with brain tumors so that a larger study can be conducted. This study will also give us some information about whether the combination of Bevacizumab and radiation has potential to become an effective treatment for regrowing brain tumors.
Bevacizumab is an experimental drug that blocks a molecule called VEGF that is found in high amounts in malignant gliomas. VEGF promotes the growth of blood vessels that bring nutrients to tumor cells. In studies with laboratory animals, Bevacizumab slowed the growth of several different types of human cancer cells by blocking the effects of VEGF. There is also evidence that Bevacizumab enhances the effects of radiation on tumor cell
Studie Overzicht
Toestand
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
New York
-
Commack, New York, Verenigde Staten, 11725
- Memorial Sloan-Kettering Cancer Center @ Suffolk
-
New York, New York, Verenigde Staten, 10065
- Memorial Sloan Kettering Cancer Center
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Recurrent malignant glioma that has failed prior radiotherapy and/or chemotherapy. Surgery for the recurrence may be offered to selected patients prior to receiving bevacizumab and IMRT on this protocol.
- MRI scan with gadolinium contrast showing geographically-circumscribed tumor < than or equal to 3.5cm. (Scan must be performed on a steroid dosage that has been stable for at least 5 days. If the steroid dose is increased between date of imaging and registration, a new baseline MRI is required).
- Patients must have recovered from the toxic effects of prior therapy:
- An interval of > than or equal to 4 weeks (28 days) from prior cytotoxic therapy
- An interval of > than or equal to 1 week (7 days) from any non-cytotoxic agents
- An interval of > than or equal to 6 weeks (42 days) from the completion of radiation therapy
- Absolute neutrophil count > than or equal to 1,500/mm3.
- Platelet count > than or equal to 100,000/mm3.
- Hemoglobin > than or equal to 10 g/dl.
- BUN and serum creatinine both < 1.5 times upper limit of normal.
- Total bilirubin both < 1.5 times upper limit of normal.
- SGOT and SGPT both < than or equal to 3 times upper limit of normal.
- Alkaline phosphatase < than or equal to 2 times upper limit of normal.
- > than or equal to 18 years of age.
- Karnofsky Performance Score > or equal to 70
- Life expectancy > or equal to 12 weeks
- Men and women with reproductive potential must agree to use an acceptable method of birth control during treatment and for six months after completion of treatment.
- Patient or their legal proxy must provide written informed consent prior to registration on study.
Exclusion Criteria:
- Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a Genentech-sponsored bevacizumab cancer study.
- Blood pressure >150 mmHg systolic and/or >100 mmHg diastolic
- Any prior history of hypertensive crisis or hypertensive encephalopathy
- Unstable angina within 12 months of study enrollment
- CTC 3.0 Grade 2 or greater congestive heart failure
- History of myocardial infarction within 12 months of study enrollment
- History of stroke or transient ischemic attack at any time
- Known CNS disease
- Known hypersensitivity to any component of bevacizumab
- History of peptic ulcer within the last 6 months
- Clinically significant peripheral vascular disease
- Evidence of bleeding diathesis or coagulopathy
- Use of ongoing anticoagulants or antiplatelet agents (aspirin, NSAIDS, etc)
- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to the first dose of bevacizumab or anticipation of need for major surgical procedure during the course of the study. (Recently resected patients may be enrolled on-study two weeks post-surgery. However, treatment with Bevacizumab will not begin until 28 days after the surgical procedure for all patients.)
- Craniotomy wound that has not sufficiently healed
- Minor surgical procedures, fine needle aspirations or core biopsies within 7 days prior to study enrollment
- Pregnant (positive pregnancy test) or lactating
- Urine protein:creatinine ratio ≥1.0 at screening
- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study enrollment
- Serious, non-healing wound, ulcer, or bone fracture
- Lung carcinoma of squamous cell histology or any histology in close proximity to a major vessel, cavitation, or history of hemoptysis
- Inability to comply with study and/or follow-up procedures
- Glioma showing prior spontaneous hemorrhage as determined from the clinical history or from any preoperative CT or MRI scan.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: 1
bevacizumab and radiation (IMRT)
|
bevacizumab 10 mg/kg IV once every two weeks on days 1 and 15 of every cycle (cycle defined as 28 days).
If the tumor volume remains < 40 cc, the patient will undergo stereotactic radiotherapy with IMRT (30Gy) beginning anywhere from day 7-10 of cycle 2 (5 doses of 6 Gy over 2 and a half weeks)
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
To test the safety of bevacizumab in patients with recurrent malignant gliomas in preparation for a larger study to test the efficacy of this drug used during the initial radiation treatment of these tumors if safety is affirmed.
Tijdsspanne: conclusion of study
|
conclusion of study
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: Philip Gutin, MD, Memorial Sloan Kettering Cancer Center
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Pathologische processen
- Hersenziekten
- Ziekten van het centrale zenuwstelsel
- Ziekten van het zenuwstelsel
- Neoplasmata per histologisch type
- Neoplasmata
- Neoplasmata per site
- Neoplasmata, glandulair en epitheel
- Ziekte attributen
- Neoplasmata, neuro-epitheliaal
- Neuro-ectodermale tumoren
- Neoplasmata, kiemcellen en embryonaal
- Neoplasmata, zenuwweefsel
- Neoplasmata van het centrale zenuwstelsel
- Neoplasmata van het zenuwstelsel
- Herhaling
- Glioom
- Hersenneoplasmata
- Fysiologische effecten van medicijnen
- Antineoplastische middelen
- Antineoplastische middelen, immunologisch
- Angiogenese-remmers
- Angiogenese modulerende middelen
- Groei stoffen
- Groeiremmers
- Bevacizumab
Andere studie-ID-nummers
- 05-092
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Hersenkanker
-
Assistance Publique Hopitaux De MarseilleOnbekendBrain Awake ChirurgieFrankrijk
-
University of Dublin, Trinity CollegeOnbekendBrain Health Gepensioneerde topsporters
-
Medical University of ViennaVoltooidPerioperatief | Brain Natriuretisch Peptide | Aanvullende zuurstof | HartrisicopatiëntenOostenrijk
-
Hospices Civils de LyonVoltooidPosterior Brain Fossa-tumoren bij kinderenFrankrijk
-
Kartal Kosuyolu Yuksek Ihtisas Education and Research...Trakya University Faculty of Medicine HospitalVoltooidHartoperatie | Desfluraan | Cardiopulmonale bypass | Coronaire Bypass Graft Chirurgie | Brain Natriuretisch Peptide | Resultaat
-
GE HealthcareCovance; i3 StatprobeVoltooidBrain Fibrillarab-niveausVerenigde Staten
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)VoltooidAdenocarcinoom van de dunne darm | Stadium III Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIA Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIB dunne darm adenocarcinoom AJCC v8 | Stadium IV Adenocarcinoom van de dunne darm AJCC v8 | Ampulla van Vater Adenocarcinoom | Stadium III... en andere voorwaardenVerenigde Staten
-
University of UtahNational Cancer Institute (NCI)WervingVermoeidheid | Sedentaire levensstijl | Gemetastaseerd prostaatcarcinoom | Stadium IV prostaatkanker AJCC (American Joint Committee on Cancer) v8 | Stadium IVA prostaatkanker AJCC (American Joint Committee on Cancer) v8 | Stadium IVB prostaatkanker AJCC (American Joint Committee on Cancer) v8Verenigde Staten
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...VoltooidBestudeer Chinese vrouwen die zich niet hebben gehouden aan de richtlijnen voor screening op mammografie van de American Cancer SocietyVerenigde Staten
-
First Affiliated Hospital Xi'an Jiaotong UniversityVoltooidHartinfarct | Revalidatie | Brain-computer-interfaceChina
Klinische onderzoeken op bevacizumab and radiation (IMRT)
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)WervingOrofaryngeale kanker | Kwaadaardige neoplasmata van mondholte en keelholteVerenigde Staten
-
Massachusetts General HospitalGenentech, Inc.WervingHepatocellulair carcinoom | Resectabel hepatocellulair carcinoomVerenigde Staten
-
Zhejiang Cancer HospitalNog niet aan het wervenNasofarynxcarcinoom
-
Benaroya Research InstituteGenentech, Inc.VoltooidProstaatkankerVerenigde Staten
-
National Taiwan University HospitalVoltooid
-
Albert Einstein College of MedicineNational Cancer Institute (NCI)BeëindigdBaarmoeder Corpus Leiomyosarcoom | Stadium IIA baarmoedersarcoom | Stadium IIB baarmoedersarcoom | Stadium IIIA baarmoedersarcoom | Stadium IIIB baarmoedersarcoom | Stadium IIIC baarmoedersarcoom | Stadium IVA baarmoedersarcoom | Stadium IVB baarmoedersarcoom | Stadium IA baarmoedersarcoom | Stadium IB... en andere voorwaardenVerenigde Staten
-
Radiation Therapy Oncology GroupNational Cancer Institute (NCI)VoltooidVolwassen reuzencelglioblastoom | Glioblastoom bij volwassenen | Volwassen gliosarcoom | Terugkerende volwassen hersentumorVerenigde Staten
-
National Cancer Institute (NCI)Radiation Therapy Oncology GroupVoltooidCervicaal adenocarcinoom | Cervicaal adenosquameus carcinoom | Cervicaal plaveiselcelcarcinoom, niet anders gespecificeerd | Stadium IIA Baarmoederhalskanker AJCC v7 | Stadium IIB Baarmoederhalskanker AJCC v6 en v7 | Stadium III Baarmoederhalskanker AJCC v6 en v7 | Stadium IB Baarmoederhalskanker...Verenigde Staten, Canada
-
National Cancer Institute (NCI)NRG Oncology; Radiation Therapy Oncology GroupVoltooidGlioblastoom | Gliosarcoom | Supratentoriaal glioblastoomVerenigde Staten, Canada, Israël
-
National Cancer Institute (NCI)Radiation Therapy Oncology GroupVoltooidStadium IA Baarmoedercorpuskanker AJCC v7 | Stadium IB Baarmoedercorpuskanker AJCC v7 | Stadium II Baarmoedercorpuskanker AJCC v7 | Endometrium Clear Cell Adenocarcinoom | Endometrium sereus adenocarcinoom | Endometrium Adenocarcinoom | Stadium IIIA Baarmoedercorpuskanker AJCC v7 | Stadium IIIB... en andere voorwaardenVerenigde Staten, Canada, Hongkong